Signs of cheer for pharma R&D returns

29 April 2024

The world’s top 20 pharma companies spent $145 billion between them on R&D investments in 2022-23 - compared to the prior year’s $139 million - according to research from the professional services firm Deloitte.

Its report Measuring the return from pharmaceutical innovation: Unleash AI’s potential is the 14th in a series analyzing the current state of R&D return on investments (ROI) for a cohort of 20 leading biopharma companies.

The research attributes the rise in R&D spend is attributed to several factors, including more complex trial requirements, regulatory changes and the impact of inflation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK